CMS recently shared proposed regulations for the Medicare prescription drug program (Part D) and the Medicare managed care program (Part C) for public comment. Several of the proposals represent important steps in improving the program and protecting beneficiaries. They include proposals ensuring meaningful differences between Part D plans; increasing drug pricing transparency, fairness and accuracy; enhancing plan oversight; improving notices; and strengthening MA plan requirements for Part D denials. One provision, which would scale back the protected drug classes is of serious concern. A few other proposals are a mixed bag needing some modification.
View the full content here